<DOC>
	<DOCNO>NCT02916693</DOCNO>
	<brief_summary>The class oral erectile dysfunction ( ED ) medication market phosphodiesterase Type 5 inhibitor ( PDE5i ) . This pilot study do evaluate effect Mirabegron , oral beta-3 adrenergic agonist , men Overactive Bladder ( OAB ) symptoms mild moderate ED .</brief_summary>
	<brief_title>Mirabegron For Erectile Dysfunction</brief_title>
	<detailed_description>ED affect 30 million men United States . The class oral medication approve ED PDE5i . These include sildenafil , tadalafil , vardenafil avanafil . Other pharmacologic option treatment ED deliver intraurethral suppository ( alprostadil ) intracavernosal injection ( alprostadil , papaverine , phentolamine , atropine ) . These invasive route administration . Men fail obtain benefit PDE5i contraindication class medication may ultimately avoid pharmacologic treatment option . An alternative class oral medication treat ED may prove benefit large population underserved men . There vitro evidence beta-3 adrenergic receptor exist human corpus cavernosum tissue . Activation receptor result vasorelaxation , suggest potential pro-erectogenic effect possible vivo . Additionally , nebivolol , beta-blocker , pro-erectogenic effect note several study . There evidence nebivolol exert beta-3 adrenergic agonism , may explain mechanism effect occur . Mirabegron available beta-3 adrenergic agonist United States . Its favorable safety profile potential therapeutic efficacy ED make suitable investigation . It hypothesize beta-3 adrenergic activation offer pharmacologic target treatment ED . Men mild , mild moderate , moderate ED symptom OAB recruit pre- post- Mirabegron administration assessment ED determine validity hypothesis . Men severe ED exclude historical data show less likely benefit oral pharmacologic therapy alone . Mirabegron approve U.S. Food Drug Administration ( FDA ) treatment adult OAB .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>presence mild ED ( IIEF EF domain score 2225 ) , mild moderate ED ( IIEF EF domain score 1721 ) moderate ED ( IIEF EF domain score 1116 ) presence OAB symptoms least 3 month least 3 micturition per day least 3 episode urgency 3 day period history pelvic surgery concurrent ED therapy history penile surgery history priapism ( unwanted , prolonged painful erection ) history neurologic disease uncontrolled hypertension : systolic blood pressure ( BP ) &gt; 140 mmHg diastolic BP &gt; 90 mmHg Stage 4 5 chronic kidney disease , Creatinine clearance rate &lt; 30ml/min moderate severe hepatic impairment concomitant use CYP2D6metabolized drug digoxin post void residual great 150 ml evidence urinary tract infection urinalysis and/or urine culture</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Mirabegron</keyword>
	<keyword>Overactive Bladder</keyword>
	<keyword>Erectile Dysfunction</keyword>
	<keyword>Beta 3 agonist</keyword>
</DOC>